Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Reverse micelle-loaded lipid nanocarriers: A novel drug delivery system for the sustained release of doxorubicin hydrochloride

Abstract :

In this study, we are pioneering new nanotechnology for the encapsulation of anticancer drugs (doxorubicin (DOX) and/or docetaxel (DOCE)), whatever their solubility and water affinity. The purpose of this study is to highlight the potential of this recently patented technology, by carrying out a thorough physicochemical characterisation of these multiscaled nanocarriers, followed by the study of an encapsulation and release model of hydrophilic anticancer drug. The formulation process is based on a low-energy nano-emulsification method and allows the generation of a structure composed of oil-based nanocarriers loaded with reverse micelles. Thanks to this, hydrophilic contents can be solubilised in the oily core of this kind of nano-emulsion along with lipophilic content. The results emphasise some original structure particularities due to the multistep formulation process, and the diffusion-based behaviour revealed for the DOX release profile that is shown to be intimately linked to the morphology of the particles.

Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.univ-angers.fr/hal-03165477
Contributeur : Okina Université d'Angers Connectez-vous pour contacter le contributeur
Soumis le : mercredi 10 mars 2021 - 16:31:17
Dernière modification le : jeudi 11 mars 2021 - 03:30:09

Identifiants

Collections

Citation

Sandy Vrignaud, Nicolas Anton, Pascal Gayet, Jean-Pierre Benoît, Patrick Saulnier. Reverse micelle-loaded lipid nanocarriers: A novel drug delivery system for the sustained release of doxorubicin hydrochloride. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V, 2011, 79 (1), pp.197-204. ⟨10.1016/j.ejpb.2011.02.015⟩. ⟨hal-03165477⟩

Partager

Métriques

Consultations de la notice

8